Patent classifications
A23G4/12
MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 REGULATES FATTY ACID UPTAKE
Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided.
MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 REGULATES FATTY ACID UPTAKE
Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided.
TRANSFER FACTOR PREPARATIONS AND ASSOCIATED METHODS
A drink includes an edible liquid or semisolid preparation and transfer factor. The drink may also include lactoferrin and one or more preservatives. An edible preparation includes a fruit component and transfer factor. The fruit component may include at least one oligoproanthocyanidin-containing fruit. The edible preparation may also include lactoferrin. One or more preservatives may also be included in the edible preparation. The drink or the edible preparation may be sterilized or pasteurized.
TRANSFER FACTOR PREPARATIONS AND ASSOCIATED METHODS
A drink includes an edible liquid or semisolid preparation and transfer factor. The drink may also include lactoferrin and one or more preservatives. An edible preparation includes a fruit component and transfer factor. The fruit component may include at least one oligoproanthocyanidin-containing fruit. The edible preparation may also include lactoferrin. One or more preservatives may also be included in the edible preparation. The drink or the edible preparation may be sterilized or pasteurized.
Chewing Gum Comprising Nicotine
A nicotine chewing gum is disclosed, the nicotine chewing gum having gum base polymers, nicotine, and microcrystalline cellulose as a carrier for the nicotine, the gum base polymers include polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight of the gum base polymers, and the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer. Also, a method for producing a nicotine chewing gum is disclosed.
Chewing Gum Comprising Nicotine
A nicotine chewing gum is disclosed, the nicotine chewing gum having gum base polymers, nicotine, and microcrystalline cellulose as a carrier for the nicotine, the gum base polymers include polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight of the gum base polymers, and the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer. Also, a method for producing a nicotine chewing gum is disclosed.
CHEWING GUM COMPOSITIONS FOR SKIN BENEFITS
Chewable compositions or specifically chewing gum contains a combination of beauty ingredients that are useful for protecting and/or maintaining healthy skin. More particularly, the chewing gum comprises a combination of collagen, Vitamin C, and Vitamin E, which may be useful for maintaining skin elasticity and protecting the skin from oxidative stress.
COMPOSITION FOR PREVENTING OR TREATING STROKE OR DEGENERATIVE BRAIN DISEASE
The present invention relates to a composition for preventing and/or treating a stroke or a degenerative brain disease comprising: at least two substances selected from the group consisting of egg yolk lecithin, glycerol, sodium oleate, medium chain triglyceride and refined fish oil; olive oil; and soybean oil. The composition of the present invention has an excellent neuroprotective effect but no toxicity or side effects, and thus can be effectively and safely used for preventing, treating or ameliorating a stroke or a degenerative brain disease.
COMPOSITION FOR PREVENTING OR TREATING STROKE OR DEGENERATIVE BRAIN DISEASE
The present invention relates to a composition for preventing and/or treating a stroke or a degenerative brain disease comprising: at least two substances selected from the group consisting of egg yolk lecithin, glycerol, sodium oleate, medium chain triglyceride and refined fish oil; olive oil; and soybean oil. The composition of the present invention has an excellent neuroprotective effect but no toxicity or side effects, and thus can be effectively and safely used for preventing, treating or ameliorating a stroke or a degenerative brain disease.
SYNERGISTIC ANTIBACTERIAL EFFECTS OF MAGNOLIA BARK EXTRACT AND L-ARGININE, N-ALPHA-LAUROYL ETHYL ESTER ON PLAQUE BIOFILM
The present disclosure relates generally to oral compositions and methods for inhibiting the formation of plaque biofilm by salivary bacteria, and more particularly, to oral compositions comprising a combination of magnolia bark extract (MBE) and L-arginine, N.sup.-lauroyl ethyl ester (LAE). The oral compositions are useful for improving oral health, including inhibiting the formation of plaque biofilm by salivary bacteria and reducing plaque adherence to teeth.